I have been an independent financial adviser for over 11 years in the city and in recent years turned my experience in finance and passion for journalism into a full time role. I perform analysis of Companies and publicize valuable information for shareholder community.
Address: 454 Cottrill Lane, Saint Louis, MO 63108, USA
Phone: (+1) 314-388-9712
Latest posts by Dorothy Owen (see all)
- Comparison: Fitbit Versa vs Apple Watch – For Health care - September 3, 2019
- Watch your heart rate while you swim – new invention in augmented reality World - September 3, 2019
- Hot Stock That Must Be in Your Portfolio: Apellis Pharmaceuticals Inc. (NASDAQ: APLS) - August 21, 2019
BURLINGAME, Calif., August 15, 2019 – Shares of Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) lost -0.76% to $3.92. The stock grabbed the investor’s attention and traded 105.422K shares as compared to its average daily volume of 214.23K shares. The stock’s institutional ownership stands at 84.40%.
Corvus Pharmaceuticals, Inc. (CRVS) reported a loss of $11.60M in its first quarter. The Burlingame, California-based company said it had a loss of 40 cents per share.
At March 31, 2019, Corvus had cash, cash equivalents and marketable securities totaling $105.80M, as contrast to cash, cash equivalents and marketable securities of $114.60M at December 31, 2018.
Research and development expenses for the three months ended March 31, 2019 totaled $9.40M contrast to $12.10M for the same period in 2018. The decrease of $2.70M was mainly because of a decrease in ciforadenant program costs.
The net loss for the three months ended March 31, 2019 was $11.60M, contrast to a net loss of $14.30M for the same period in 2018. Total stock compensation expense for the three months ended March 31, 2019 was $2.00M contrast to $1.80M of total stock compensation expense for the same period in 2018.
CRVS has a market value of $95.45M while its EPS was booked as $-1.56 in the last 12 months. The stock has 24.35M shares outstanding. Beta value of the company was 1.03; beta is used to measure riskiness of the security. Analyst recommendation for this stock stands at 1.50.